Клинические рекомендации по диагностике и ведению больных со злокачественной мезотелиомой плевры (часть 2-я)
https://doi.org/10.18093/0869-0189-2018-28-6-655-679
Аннотация
По материалам: Woolhouse I., Bishop L., Darlison L., De Fonseka D., Edey A., Edwards J., Faivre-Finn C., Fennell D.A., Holmes S., Kerr K.M., Nakas A., Peel T., Rahman N.M., Slade M., Steele J., Tsim S., Maskell N.A. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018; 73 (Suppl. 1): i1–i30. DOI: 10.1136/thoraxjnl-2017-211321
Список литературы
1. Royal College of Physicians. National Lung Cancer Audit: pleural mesothelioma report 2016. Available at: https://www.rcplondon.ac.uk/projects/outputs/national-lung-cancer-audit-pleural-mesothelioma-report-2016
2. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007; 62 (Suppl. 2): ii1–ii19. DOI: 10.1136/thx.2007.087619.
3. Beckett P., Edwards J., Fennell D. et al. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015; 88 (3): 344–348. DOI: 10.1016/j.lungcan.2015.03.005.
4. Yates D.H., Corrin B., Stidolph P.N., Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997; 52 (6): 507–512. DOI: 10.1136/thx.52.6.507.
5. Aguilar-Madrid G., Robles-Perez E., Juarez-Perez C.A. et al. Case-control study of pleural mesothelioma in workers with social security in Mexico. Am. J. Ind. Med. 2010; 53 (3): 241–251. DOI: 10.1002/ajim.20780.
6. Peto J., Rake С., Gilham С., Hatch J. Occupational, domestic and environmental mesothelioma risks in Britain: A case-control study. Health and Safety Executive. 2009; RR696. Available at: http://www.hse.gov.uk/research/rrpdf/rr696.pdf
7. Bourdes V., Boffetta P., Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur. J. Epidemiol. 2000; 16 (5): 411–417.
8. Cigognetti M., Lonardi S., Fisogni S. et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod. Pathol. 2015; 28 (8): 1043–1057. DOI: 10.1038/modpathol.2015.65.
9. Tanrikulu A.C., Abakay A., Kaplan M.A. et al. A clinical, radiographic and laboratoryevaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010; 80 (6): 480–487. DOI: 10.1159/000321370.
10. Adams V.I., Unni K.K., Muhm J.R. et al. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986; 58 (7): 1540–1551.
11. Rusch V.W., Chansky K., Kindler H.L. et al. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J. Thorac. Oncol. 2016; 11 (12): 2112–2119. DOI: 10.1016/j.jtho.2016.09.124.
12. Sugarbaker D.J., Strauss G.M., Lynch T.J. et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J. Clin. Oncol. 1993; 11 (6): 1172–1178. DOI: 10.1200/JCO.1993.11.6.1172.
13. Hallifax R.J., Haris M., Corcoran J.P. et al. Role of CT in assessing pleural malignancy prior to thoracoscopy. Thorax. 2015; 70 (2): 192–193. DOI: 10.1136/thoraxjnl-2014-206054.
14. Salonen O., Kivisaari L., Standertskjöld-Nordenstam C.G. et al. Computed tomography of pleural lesions with special reference to the mediastinal pleura. Acta. Radiol. Diagn. 1986; 27 (5): 527–531.
15. Seely J.M., Nguyen E.T., Churg A.M. et al. Malignant pleural mesothelioma: computed tomography and correlation with histology. Eur. J. Radiol. 2009; 70 (3): 485–491. DOI: 10.1016/j.ejrad.2008.02.004.
16. Okten F., Koksal D., Onal M. et al. Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos. Clin. Imaging. 2006; 30 (3): 177–180. DOI: 10.1016/j.clinimag.2005.12.027.
17. Knuuttila A., Kivisaari L., Kivisaari A. et al. Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma. Acta Radiol. 2001; 42 (5): 502–507.
18. Metintas M., Ucgun I., Elbek O. et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur. J. Radiol. 2002; 41 (1): 1–9.
19. Hierholzer J., Luo L., Bittner R.C. et al. MRI and CT in the differential diagnosis of pleural disease. Chest. 2000; 118 (3): 604–609.
20. Leung A.N., Müller N.L., Miller R.R. CT in differential diagnosis of diffuse pleural disease. Am. J. Roentgenol. 1990; 154 (3): 487–492. DOI: 10.2214/ajr.154.3.2106209.
21. Yilmaz U., Polat G., Sahin N. et al. CT in differential diagnosis of benign and malignant pleural disease. Monaldi Arch. Chest Dis. 2005; 63 (1): 17–22. DOI: 10.4081/monaldi.2005.653.
22. Qureshi N.R., Rahman N.M., Gleeson F.V. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009; 64 (2): 139–143. DOI: 10.1136/thx.2008.100545.
23. Elboga U., Yılmaz M., Uyar M. et al. The role of FDG PET-CT in differential diagnosis of pleural pathologies. Rev. Esp. Med. Nucl. Imagen Mol. 2012; 31 (4): 187–191. DOI: 10.1016/j.remn.2011.06.002.
24. Porcel J.M., Hernandez P., Martinez-Alonso M. et al. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a metaanalysis. Chest. 2015; 147 (2): 502–512. DOI: 10.1378/chest.14-0820.
25. Benard F., Sterman D., Smith R.J. et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998; 114 (3): 713–722.
26. Abe Y., Tamura K., Sakata I. et al. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. Oncol. Rep. 2012; 27 (2): 333–338. DOI: 10.3892/or.2011.1520.
27. Yildirim H., Metintas M., Entok E. et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J. Thorac. Oncol. 2009; 4 (12): 1480–1484. DOI: 10.1097/JTO.0b013e3181c0a7ff.
28. Treglia G., Sadeghi R., Annunziata S. et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. Acad. Radiol. 2014; 21 (1): 11–20. DOI: 10.1016/j.acra.2013.09.015.
29. Coolen J., De Keyzer F., Nafteux P. et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging-initial experience. Radiology. 2012; 263 (3): 884–892. DOI: 10.1148/radiol.12110872.
30. Boraschi P., Neri S., Braccini G. et al. Magnetic resonance appearance of asbestosrelated benign and malignant pleural diseases. Scand. J. Work Environ Health. 1999; 25 (1): 18–23. DOI: 10.5271/sjweh.378.
31. Revelli M., Chiesa F., Del Prato A. et al. Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease. Br. J. Radiol. 2016; 89 (1064): 2–7. DOI: 10.1259/bjr.20160289.
32. Gill R.R., Umeoka S., Mamata H. et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. Am. J. Roentgenol. 2010; 195 (2): W125–W130. DOI: 10.2214/AJR.09.3519.
33. Coolen J., De Keyzer F., Nafteux P. et al. Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging. Radiology. 2015; 274 (2): 576–584. DOI: 10.1148/radiol.14132111.
34. Giesel F.L., Bischoff H., von Tengg-Kobligk H. et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006; 129 (6): 1570–1576. DOI: 10.1378/chest.129.6.1570.
35. Wilcox B.E., Subramaniam R.M., Peller P.J. et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin. Lung Cancer. 2009; 10 (4): 244–248. DOI: 10.3816/CLC.2009.n.033.
36. Plathow C., Staab A., Schmaehl A. et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest. Radiol. 2008; 43 (10): 737–744. DOI: 10.1097/RLI.0b013e3181817b3d.
37. Stewart D., Waller D., Edwards J. et al. Is there a role for pre-operative contrastenhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma? Eur. J. Cardiothorac. Surg. 2003; 24 (6): 1019–1024.
38. Schouwink J.H., Kool L.S., Rutgers E.J. et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann. Thorac. Surg. 2003; 75 (6): 1715–1718.
39. Heelan R.T., Rusch V.W., Begg C.B. et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am. J. Roentgenol. 1999; 172 (4): 1039–1047. DOI: 10.2214/ajr.172.4.10587144.
40. Niccoli-Asabella A., Notaristefano A., Rubini D. et al. 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibersexposedpatients (comparison to standard diagnostic follow-up). Clin. Imaging. 2013; 37 (6): 1098–1103. DOI: 10.1016/j.clinimag.2013.06.009.
41. Knuuttila A., Halme M., Kivisaari L. et al. The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma. Lung. Cancer. 1998; 22 (3): 215–225.
42. Patz E.F., Shaffer K., Piwnica-Worms D.R. et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. Am. J. Roentgenol. 1992; 159: 961–966. DOI: 10.2214/ajr.159.5.1414807.
43. Erasmus J.J., Truong M.T., Smythe W.R. et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J. Thorac. Cardiovasc. Surg. 2005; 129: 1364–1370. DOI: 10.1016/j.jtcvs.2004.10.034.
44. Fiore D., Baggio V., Sotti G. et al. Imaging before and after multimodal treatment for malignant pleural mesothelioma. Radiol. Med. 2006; 111 (3): 355–364. DOI: 10.1007/s11547-006-0034-3.
45. Flores R.M., Akhurst T., Gonen M. et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2003; 126 (1): 11–16.
46. Frauenfelder T., Kestenholz P., Hunziker R. et al. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma. J. Comput. Assist. Tomogr. 2015; 39 (2): 160–165. DOI: 10.1097/RCT.0000000000000174.
47. Genestreti G., Moretti A., Piciucchi S. et al. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. Technol. Cancer Res. Treat. 2012; 11 (2): 163–167. DOI: 10.7785/tcrt.2012.500245.
48. Martini K., Meier A., Opitz I. et al. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. Lung Cancer. 2016; 94: 40–45. DOI: 10.1016/j.lungcan.2016.01.017.
49. Pinelli V., Roca E., Lucchini S. et al. Positron emission tomography/computed tomography for the pleural staging of malignant pleural mesothelioma: how accurate is it? Respiration. 2015; 89 (6): 558–564. DOI: 10.1159/000381922.
50. Zahid I., Sharif S., Routledge T. et al. What is the best way to diagnose and stage malignant pleural mesothelioma? Interact. Cardiovasc. Thorac. Surg. 2011; 12 (2): 254–259. DOI: 10.1510/icvts.2010.255893.
51. Sharif S., Zahid I., Routledge T. et al. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact. Cardiovasc. Thorac. Surg. 2011; 12 (5): 806–811. DOI: 10.1510/icvts.2010.255901.
52. Galateau-Salle F., Churg A., Roggli V. et al. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J. Thorac. Oncol. 2016; 11 (2): 142–154. DOI: 10.1016/j.jtho.2015.11.005.
53. Husain A.N., Colby T., Ordonez N. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2013; 137 (5): 647–667. DOI: 10.5858/arpa.2012-0214-OA.
54. Wu D., Hiroshima K., Matsumoto S. et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am. J. Clin. Pathol. 2013; 139 (1): 39–46. DOI: 10.1309/AJCPT94JVWIHBKRD.
55. Hida T., Matsumoto S., Hamasaki M. et al. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue. Cancer Sci. 2015; 106 (11): 1635–1641. DOI: 10.1111/cas.12769.
56. Walters J., Maskell N.A. Biopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res. 2011; 189: 45–55. DOI: 10.1007/978-3-642-10862-4_4.
57. Segal A., Sterrett G.F., Frost F.A. et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013; 45 (1): 44–48. DOI: 10.1097/PAT.0b013e32835bc848.
58. Cui A., Jin X.G., Zhai K. et al. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open. 2014; 4 (2): e004145. DOI: 10.1136/bmjopen-2013-004145.
59. Hu Z.D., Liu X.F., Liu X.C. et al. Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. Clin. Chim. Acta. 2014; 433: 44–48. DOI: 10.1016/j.cca.2014.02.024.
60. Lin H., Shen Y.C., Long H.Y. et al. Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis. Int. J. Clin. Exp. Med. 2014; 7 (5): 1289–1296.
61. Kirschner M.B., Pulford E., Hoda M.A. et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br. J. Cancer 2015; 113 (6): 963–969. DOI: 10.1038/bjc.2015.286.
62. Creaney J., Francis R.J., Dick I.M. et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin. Cancer Res. 2011; 17 (5): 1181–1189. DOI: 10.1158/1078-0432.CCR-10-1929.
63. Creaney J., Dick I.M., Segal A. et al. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013; 82 (3): 491–498. DOI: 10.1016/j.lungcan.2013.09.016.
64. Franko A., Dolzan V., Kovac V. et al. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis. Markers. 2012; 32 (2): 123–131. DOI: 10.3233/DMA-2011-0866.
65. Ghanim B., Hoda M.A., Klikovits T. et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br. J. Cancer. 2014; 110 (4): 984–990. DOI: 10.1038/bjc.2013.815.
66. Grigoriu B.D., Chahine B., Vachani A. et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am. J. Respir. Crit. Care Med. 2009; 179 (10): 950–954. DOI: 10.1164/rccm.200807-1125OC.
67. Hirayama N., Tabata C., Tabata R. et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir. Med. 2011; 105 (1): 137–412. DOI: 10.1016/j.rmed.2010.10.010.
68. Hollevoet K., Nackaerts K., Gosselin R. et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J. Thorac. Oncol. 2011; 6 (11): 1930–1937. DOI: 10.1097/JTO.0b013e3182272294.
69. Kao S.C., Klebe S., Henderson D.W. et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J. Thorac. Oncol. 2011; 6 (11): 1923–1929. DOI: 10.1097/JTO.0b013e31822a3740.
70. Kao S.C., Harvie R., Paturi F. et al. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 2012; 75 (2): 248–254. DOI: 10.1016/j.lungcan.2011.06.007.
71. Pinato D.J., Mauri F.A., Ramakrishnan R. et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J. Thorac. Oncol. 2012; 7 (3): 587–594. DOI: 10.1097/JTO.0b013e31823f45c1.
72. Thylén A., Hjerpe A., Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001; 92 (5): 1224–1230.
73. Wheatley-Price P., Yang B., Patsios D. et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J. Clin. Oncol. 2010; 28 (20): 3316–3322. DOI: 10.1200/JCO.2009.26.9944.
74. Zhang Y., He J., Zhang F. et al. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J. Exp. Clin. Cancer Res. 2013; 32: 7. DOI: 10.1186/1756-9966-32-7.
75. Hooper C.E., Lyburn I.D., Searle J. et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br. J. Cancer. 2015; 112 (7): 1175–1182. DOI: 10.1038/bjc.2015.62.
76. Hoda M.A., Dong Y., Rozsas A. et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur. J. Cancer. 2016; 63: 64–73. DOI: 10.1016/j.ejca.2016.04.018.
77. Park E.K., Sandrini A., Yates D.H. et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008; 178 (8): 832–837. DOI: 10.1164/rccm.200802-258OC.
78. Filiberti R., Marroni P., Spigno F. et al. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos. Oncology. 2014; 86 (1): 33–43. DOI: 10.1159/000355687.
79. Bayram M., Dongel I., Akbaş A. et al. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung. 2014; 192 (1): 197–203. DOI: 10.1007/s00408-013-9526-9.
80. Gube M., Taeger D., Weber D.G. et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch. Toxicol 2011; 85 (3): 185–92. DOI: 10.1007/s00204-010-0580-2.
81. Rodriguez Portal J.A., Rodriguez Becerra E., Rodriguez Rodriguez D. et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestosrelated pleural disease: relation with past asbestos exposure. Cancer Epidemiol. Biomarkers Prev. 2009; 18 (2): 646–650. DOI: 10.1158/1055-9965.EPI-08-0422.
82. Bottomley A., Coens C., Efficace F. et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2007; 25 (36): 5770–5776. DOI: 10.1200/JCO.2007.12.5294.
83. Curran D., Sahmoud T., Therasse P. et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J. Clin. Oncol. 1998; 16 (1): 145–152. DOI: 10.1200/JCO.1998.16.1.145.
84. Fennell D.A., Parmar A., Shamash J. et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J. Clin. Oncol. 2005; 23 (1): 184–189. DOI: 10.1200/JCO.2005.07.050.
85. Meniawy T.M., Creaney J., Lake R.A. et al. Existing models, but not neutrophilto – lymphocyte ratio, are prognostic in malignant mesothelioma. Br. J. Cancer. 2013; 109 (7): 1813–1820. DOI: 10.1038/bjc.2013.504.
86. Edwards J.G., Abrams K.R., Leverment J.N. et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000; 55 (9): 731–735. DOI: 10.1136/thorax.55.9.731.
87. Herndon J.E., Green M.R., Chahinian A.P. et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113 (3): 723–731. DOI: 10.1378/chest.113.3.723.
88. Clive A.O., Kahan B.C., Hooper C.E. et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014; 69 (12): 1098–1104. DOI: 10.1136/thoraxjnl-2014-205285.
89. Brims F.J., Meniawy T.M., Duffus I. et al. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J. Thorac. Oncol. 2016; 11 (4): 573–582. DOI: 10.1016/j.jtho.2015.12.108.
90. Gemba K., Fujimoto N., Aoe K. et al. Treatment and survival analyses of malignant mesothelioma in Japan. Acta. Oncol. 2013; 52 (4): 803–808. DOI: 10.3109/0284186X.2012.709948.
91. Milano M.T., Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J. Thorac. Oncol. 2010; 5 (11): 1841–1848. DOI: 10.1097/JTO.0b013e3181f1cf2b.
92. Taioli E., Wolf A.S., Camacho-Rivera M. et al. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann. Thorac. Surg. 2014; 98 (3): 1020–1024. DOI: 10.1016/j.athoracsur.2014.04.040.
93. Rintoul R.C., Ritchie A.J., Edwards J.G. et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014; 384 (9948): 1118–1127. DOI: 10.1016/S0140-6736(14)60418-9.
94. Davies H.E., Mishra E.K., Kahan B.C. et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012; 307 (22): 2383–2389. DOI: 10.1001/jama.2012.5535.
95. Fysh E.T., Tan S.K., Read C.A. et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013; 68 (6): 594–596. DOI: 10.1136/thoraxjnl-2012-203043.
96. Bielsa S., Hernandez P., Rodriguez-Panadero F. et al. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung. 2011; 189 (2): 151–155. DOI: 10.1007/s00408-011-9283-6.
97. Aelony Y., Yao J.F. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005; 10 (5): 649–655. DOI: 10.1111/j.1440-1843.2005.00763.x.
98. Brancatisano R.P., Joseph M.G., McCaughan B.C. Pleurectomy for mesothelioma. Med. J. Aust. 1991; 154 (7): 455–460.
99. Barbetakis N., Asteriou C., Papadopoulou F. et al. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J. Cardiothorac. Surg. 2010; 5: 27. DOI: 10.1186/1749-8090-5-27.
100. Basso S.M., Mazza F., Marzano B. et al. Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results. Anticancer Res. 2012; 32 (11): 5131–5134.
101. Medford A.R., Agrawal S., Free C.M., Bennett J.A. A local anaesthetic video-assisted thoracoscopy service: prospective performance analysis in a UK tertiary respiratory centre. Lung Cancer. 2009; 66 (3): 355–358. DOI: 10.1016/j.lungcan.2009.02.023.
102. Rice D., Rusch V., Pass H. et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J. Thorac. Oncol. 2011; 6 (8): 1304–1312. DOI: 10.1097/JTO.0b013e3182208e3f.
103. Treasure T., Lang-Lazdunski L., Waller D. et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. Lancet Oncol. 2011; 12 (8): 763–772. DOI: 10.1016/S1470-2045(11)70149-8.
104. Mollberg N.M., Vigneswaran Y., Kindler H.L. et al. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann. Thorac. Surg. 2012; 94 (4): 1086–1092. DOI: 10.1016/j.athoracsur.2012.05.102.
105. Bölükbas S., Eberlein M., Schirren J. Prospective study on functional results after lungsparing radical pleurectomy in the management of malignant pleural mesothelioma. J. Thorac. Oncol. 2012; 7 (5): 900–905. DOI: 10.1097/JTO.0b013e31824de2dc.
106. Burkholder D., Hadi D., Kunnavakkam R. et al. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann. Thorac. Surg. 2015; 99 (5): 1775–1780. DOI: 10.1016/j.athoracsur.2015.01.058.
107. Ploenes T., Osei-Agyemang T., Krohn A. et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc. Thorac. Ann. 2013; 21 (1): 48–55. DOI: 10.1177/0218492312454017.
108. Cao C.Q., Yan T.D., Bannon P.G., McCaughan B.C. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Oncol. 2010; 5 (10): 1692–1703. DOI: 10.1097/JTO.0b013e3181ed0489.
109. Cao C., Tian D., Manganas C. et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann. Cardiothorac. Surg. 2012; 1 (4):428–437. DOI: 10.3978/j.issn.2225-319X.2012.11.07.
110. Cao C., Tian D.H., Pataky K.A., Yan T.D. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013; 81 (3): 319–327. DOI: 10.1016/j.lungcan.2013.04.024.
111. Cao C., Tian D., Park J. et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014; 83 (2): 240–245. DOI: 10.1016/j.lungcan.2013.11.026.
112. Lim E. A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study. Lung Cancer. 2016; 91 (Suppl. 1): S71. DOI: 10.1016/S0169-5002(16)30212-4.
113. Treasure T., Utley M., O’Byrne K. MARS: a sense of perspective and an inconvenient truth. J. Thorac. Oncol. 2013; 8 (5): e48–e49. DOI: 10.1097/JTO.0b013e318286c72b.
114. Taioli E., Wolf A.S., Flores R.M. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann. Thorac. Surg. 2015; 99 (2): 472–480. DOI: 10.1016/j.athoracsur.2014.09.056.
115. Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21 (14): 2636–2644. DOI: 10.1200/JCO.2003.11.136.
116. van Meerbeeck J.P., Gaafar R., Manegold C. et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23 (28): 6881–6889. DOI: 10.1200/JCO.20005.14.589.
117. Muers M.F., Stephens R.J., Fisher P. et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008; 371 (9625): 1685–1694. DOI: 10.1016/S0140-6736(08)60727-8.
118. Mordant P., Loriot Y., Soria J.C., Deutsch E. MVP and vinorelbine for malignant pleural mesothelioma. Lancet. 2008; 372 (9639): 629. DOI: 10.1016/S0140-6736(08)61273-8.
119. Zalcman G., Mazieres J., Margery J. et al. Bevacizumab 15mg/kg plus cisplatinpemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J. Clin. Oncology. 2015; 33 (15, Suppl. 1): 7500.
120. Santoro A., O’Brien M.E., Stahel R.A. et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaпve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J. Thorac. Oncol. 2008; 3 (7): 756–763. DOI: 10.1097/JTO.0b013e31817c73d6.
121. Buikhuisen W.A., Hiddinga B.I., Baas P., van Meerbeeck J.P. Second line therapy in malignant pleural mesothelioma: A systematic review. Lung Cancer. 2015; 89 (3): 223–231. DOI: 10.1016/j.lungcan.2015.06.018.
122. Jassem J., Ramlau R., Santoro A. et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 2008; 26 (10): 1698–1704. DOI: 10.1200/JCO.2006.09.9887.
123. Krug L.M., Kindler H.L., Calvert H. et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet. Oncol. 2015; 16 (4): 447–456. DOI: 10.1016/S1470-2045(15)70056-2.
124. Thapa B., Salcedo A., Lin X. et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J. Thorac. Oncol. 2017; 12 (5): 850–859. DOI: 10.1016/j.jtho.2017.02.013.
125. Alley E.W., Lopez J., Santoro A. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18 (5): 623–630. DOI: 10.1016/S1470-2045(17)30169-9.
126. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995; 108 (3): 754–758. DOI: 10.1378/chest.108.3.754.
127. Bydder S., Phillips M., Joseph D.J. et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br. J. Cancer. 2004; 91 (1): 9–10. DOI: 10.1038/sj.bjc.6601957.
128. O’Rourke N., Garcia J.C., Paul J. et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother. Oncol. 2007; 84 (1): 18–22. DOI: 10.1016/j.radonc.2007.05.022.
129. Clive A.O., Taylor H., Dobson L. et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016; 17 (8): 1094–1104. DOI: 10.1016/S1470-2045(16)30095-X.
130. Lee C., Bayman N., Swindell R., Faivre-Finn C. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer. 2009; 66 (2): 150–156. DOI: 10.1016/j.lungcan.2009.06.014.
131. Bayman N., Ardron D., Ashcroft L. et al. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open. 2016; 6 (1): e010589. DOI: 10.1136/bmjopen-2015-010589.
132. de Perrot M., Feld R., Leighl N.B. et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2016; 151 (2): 468–475. DOI: 10.1016/j.jtcvs.2015.09.129.
133. Linden CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur. Respir. J. 1996; 9 (12): 2565–2572.
134. Rimner A., Spratt D.E., Zauderer M.G. et al. Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2014; 90 (2): 394–401. DOI: 10.1016/j.ijrobp.2014.05.032.
135. Allen A.M., Czerminska M., Jänne P.A. et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65 (3): 640–645. DOI: 10.1016/j.ijrobp.2006.03.012.
136. Allen A.M., Den R., Wong J.S. et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int. J. Radiat. Oncol. Biol. Phys. 2007; 68 (5): 1366–1374. DOI: 10.1016/j.ijrobp.2007.02.047.
137. Bille A., Belcher E., Raubenheimer H. et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals. Gen. Thorac. Cardiovasc. Surg. 2012; 60 (5): 289–296. DOI: 10.1007/s11748-011-0915-9.
138. Bölükbas S., Manegold C., Eberlein M. et al. Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011; 71 (1): 75–81. DOI: 10.1016/j.lungcan.2009.08.019.
139. Flores R.M., Krug L.M., Rosenzweig K.E. et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J. Thorac. Oncol. 2006; 1 (4): 289–295. DOI: 10.1016/S1556-0864(15)31583-5.
140. Kristensen C.A., Nottrup T.J., Berthelsen A.K. et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma Radiother. Oncol. 2009; 92: 96–99. DOI: 10.1016/j.radonc.2009.03.011.
141. Lucchi M., Chella A., Melfi F. et al. Four-modality therapy in malignant pleural mesothelioma: a phase II study. J. Thorac. Oncol. 2007; 2 (3): 237–242. DOI: 10.1097/JTO.0b013e318031d05c.
142. Minatel E., Trovo M., Polesel J. et al. Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. J. Thorac. Oncol. 2012; 7 (12): 1862–1866. DOI: 10.1097/JTO.0b013e318272601f.
143. Minatel E., Trovo M., Polesel J. et al. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer. 2014; 83 (1): 78–82. DOI: 10.1016/j.lungcan.2013.10.013.
144. Rice D.C., Smythe W.R., Liao Z. et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69 (2): 350–357. DOI: 10.1016/j.ijrobp.2007.03.011.
145. Pagan V., Ceron L., Paccagnella A., Pizzi G. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J. Cardiovasc. Surg. 2006; 47 (5): 595–601.
146. Rusch V.W., Rosenzweig K., Venkatraman E. et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2001; 122 (4): 788–795. DOI: 10.1067/mtc.2001.116560.
147. Tonoli S., Vitali P., Scotti V. et al. Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother. Oncol. 2011; 101 (2): 311–315. DOI: 10.1016/j.radonc.2011.09.025.
148. Van Schil P.E., Baas P., Gaafar R. et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur. Respir. J. 2010; 36 (6): 1362–1369. DOI: 10.1183/09031936.00039510.
149. Weder W., Stahel R.A., Bernhard J. et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 2007; 18 (7): 1196–1202. DOI: 10.1093/annonc/mdm093.
150. Stahel R.A., Riesterer O., Xyrafas A. et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015; 16 (16): 1651–1658. DOI: 10.1016/S1470-2045(15)00208-9.
151. Rimner A., Zauderer M.G., Gomez D.R. et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (imprint) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2016; 34 (23): 2761–2768. DOI: 10.1200/JCO.2016.67.2675.
152. Bissett D., Macbeth F.R., Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. 1991; 3 (6): 315–317. DOI: 10.1016/S0936-6555(05)80582-5.
153. MacLeod N., Chalmers A., O’Rourke N. et al. Is radiotherapy useful for treating pain in mesothelioma? A phase II trial. J. Thorac. Oncol. 2015; 10 (6): 944–950. DOI: 10.1097/JTO.0000000000000499.
154. Davis S.R., Tan L., Ball D.L. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Austral. Radiol. 1994; 38 (3): 212–214. DOI: 10.1111/j.1440-1673.1994.tb00177.x.
155. de Graaf-Strukowska L., van der Zee J., van Putten W., Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura – a single-institution experience with 189 patients. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43 (3): 511–516. DOI: 10.1016/S0360-3016(98)00409-X.
156. Jenkins P., Milliner R., Salmon C. Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma. Eur. J. Cancer. 2011; 47 (14): 2143–2149. DOI: 10.1016/j.ejca.2011.05.012.
157. Chapman E., Berenstein E.G., Dieguez M., Ortiz Z. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst. Rev. 2006; (3): CD003880. DOI: 10.1002/14651858.CD003880.pub4.
158. Macleod N., Price A., O’Rourke N. et al. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2014; 83 (2): 133–138. DOI: 10.1016/j.lungcan.2013.11.004.
159. Jackson M.B., Pounder D., Price C. et al. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax. 1999; 54 (3): 238–241. DOI: 10.1136/thx.54.3.238.
160. McNair A.G., Choh C.T., Metcalfe C. et al. Maximising recruitment into randomized controlled trials: the role of multidisciplinary cancer teams. Eur. J. Cancer. 2008; 44 (17): 2623–2626. DOI: 10.1016/j.ejca.2008.08.009.
161. Taylor C., Shewbridge A., Harris J., Green J.S. Benefits of multidisciplinary teamwork in the management of breast cancer. Breast Cancer. 2013; (5): 79–85. DOI: 10.2147/BCTT.S35581.
162. Taplin S.H., Weaver S., Salas E. et al. Reviewing cancer care team effectiveness. J. Oncol. Pract. 2015; 11 (3): 239–246. DOI: 10.1200/JOP.2014.003350.
163. Munro A.J., Swartzman S. What is a virtual multidisciplinary team (vMDT)? Br. J. Cancer. 2013; 108 (12): 2433–2441. DOI: 10.1038/bjc.2013.231.
164. Bibby A.C., Williams K., Smith S. et al. What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. BMJ Open. 2016; 6 (9): e012092. DOI: 10.1136/bmjopen-2016-012092.
165. NICE. Lung cancer: diagnosis and management, 2011. CG121. Available at: https://www.nice.org.uk/guidance/cg121/resources/lung-cancer-diagnosis-and-management-35109444863941
166. Granieri A., Tamburello S., Tamburello A. et al. Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers. Neuropsychiatr. Dis. Treat. 2013; (9): 1193–1202. DOI: 10.2147/NDT.S48965.
167. Arber A., Spencer L. ’It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013; 22 (7):1528–1533. DOI: 10.1002/pon.3162.
168. Clayson H., Seymour J., Noble B. Mesothelioma from the patient’s perspective. Hematol. Oncol. Clin. North Am. 2005; 19 (6): 1175–1190. DOI: 10.1016/j.hoc.2005.09.003.
169. Ball H., Moore S., Leary A. A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer. Eur. J. Oncol. Nurs. 2016; (25): 62–67. DOI: 10.1016/j.ejon.2016.09.007.
170. Moore S., Teehan C., Cornwall A. et al. ’Hands of Time’: the experience of establishing a support group for people affected by mesothelioma. Eur. J. Cancer. Care. 2008; 17 (6): 585–592. DOI: 10.1111/j.1365-2354.2007.00912.x.
171. Chamming’s S., Clin B., Brochard P. et al. Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme. Am. J. Ind. Med. 2013; 56 (2): 146–154. DOI: 10.1002/ajim.22106.
172. Cree M.W., Lalji M., Jiang B. et al. Under-reporting of compensable mesothelioma in Alberta. Am. J. Ind. Med. 2009; 52 (7): 526–533. DOI: 10.1002/ajim.20705.
173. Kuschner W.G., Varma R., Flores R., Carriere K.C. Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation. Am. J. Med. Sci. 2012; 343: 206–9. DOI: 10.1002/ajim.20705.
174. Ak G., Metintas M., Metintas S. et al. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur. J. Radiol. 2010; 74 (1): 130–135. DOI: 10.1016/j.ejrad.2009.02.002.
175. Armato S.G., Nowak A.K., Francis R.J. et al. Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions. J. Thorac. Oncol. 2014; 9 (8): 1187–1194. DOI: 10.1097/JTO.0000000000000211.
176. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 2004; 15 (2): 257–260.
177. Ceresoli G.L., Chiti A., Zucali P.A. et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J. Clin. Oncol. 2006; 24 (28): 4587–4593. DOI: 10.1200/JCO.2006.06.8999.
178. Frauenfelder T., Tutic M., Weder W. et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur. Respir. J. 2011; 38 (1): 162–168. DOI: 10.1183/09031936.00146110.
179. Hilmi O., Güntülü Ak., Selma M. et al. Relationship between tumour size of MPM and its response to chemotherapy. J. Health Sci. 2007; 53 (1): 23–30. DOI: 10.1248/jhs.53.23.
180. Nowak A.K. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer. 2005; 49 (Suppl. 1): S37–S40. DOI: 10.1016/j.lungcan.2005.03.030.
181. Plathow C., Klopp M., Thieke C. et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur. Radiol. 2008; 18 (8): 1635–1643. DOI: 10.1007/s00330-008-0918-9.
182. van Klaveren R.J., Aerts J.G., de Bruin H. et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004; 43 (1): 63–69. DOI: 10.1016/S0169-5002(03)00292-7.
183. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 2004; 15 (2): 257–260.
184. Plathow C., Klopp M., Thieke C. et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur. Radiol. 2008; 18 (8): 1635–1643. DOI: 10.1007/s00330-008-0918-9.
185. NICE. Suspected cancer: recognition and referral, 2015. NG 12. Available at: https://www.nice.org.uk/guidance/ng12
186. Carella R., Deleonardi G., D’Errico A. et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am. J. Surg. Pathol. 2001; 25 (1): 43–50.
187. Klebe S., Nurminen M., Leigh J., Henderson D.W. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology. 2009; 41 (2): 140–148. DOI: 10.1080/00313020802579250.
188. Lucas D.R., Pass H.I., Madan S.K. et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003; 42 (3): 270–279. DOI: 10.1046/j.1365-2559.2003.01583.x.
189. Ordóñez N.G. Mesothelioma with signet-ring cell features: report of 23 cases. Mod. Pathol. 2013; 26 (3): 370–384. DOI: 10.1038/modpathol.2012.172.
190. Brockstedt U., Gulyas M., Dobra K. et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am. J. Clin. Pathol. 2000; 114 (2): 203–209. DOI: 10.1309/QHCA-8594-TA7P-0DVQ.
191. Comin C.E., Dini S., Novelli L. et al. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am. J. Surg. Pathol. 2006; 30 (4): 463–469.
192. Comin C.E., Novelli L., Boddi V. et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum. Pathol. 2001; 32 (5): 529–536. DOI: 10.1053/hupa.2001.24329.
193. Cury P.M., Butcher D.N., Corrin B., Nicholson A.G. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 1999; 189: 251–257. DOI: 10.1002/(SICI)1096-9896(199910)189:2%3C251::AID-PATH412%3E3.0.CO;2-F.
194. Cury P.M., Butcher D.N., Fisher C. et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod. Pathol. 2000; 13 (2): 107–112. DOI: 10.1038/modpathol.3880018.
195. Takeshima Y., Amatya V.J., Kushitani K. et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009; 54 (4): 667–676. DOI: 10.1097/SLA.0000000000002373.
196. Roberts F., Harper C.M., Downie I., Burnett R.A. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am. J. Clin. Pathol. 2001; 116 (2): 253–262. DOI: 10.1309/XL6K-8E62-9FLD-V8Q8.
197. Mimura T., Ito A., Sakuma T. et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007; 109 (5): 933–938. DOI: 10.1002/cncr.22477.
198. Miettinen M., Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am. J. Surg. Pathol. 2003; 27 (2): 150–158.
199. Leers M.P., Aarts M.M., Theunissen P.H. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology. 1998; 32 (3): 209–216. DOI: 10.1046/j.1365-2559.1998.00349.x.
200. Klebe S., Brownlee N.A., Mahar A. et al. Sarcomatoid mesothelioma: a clinicalpathologic correlation of 326 cases. Mod. Pathol. 2010; 23 (3): 470–479. DOI: 10.1038/modpathol.2009.
201. Gotzos V., Vogt P., Celio M.R. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol. Res. Pract. 1996; 192 (2): 137–147. DOI: 10.1016/S0344-0338(96)80208-1.
202. Attanoos R.L., Goddard H., Gibbs A.R. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology. 1996; 29 (3): 209–215. DOI: 10.1111/j.1365-2559.1996.tb01393.x.
203. Brown R.W., Clark G.M., Tandon A.K., Allred D.C. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum. Pathol. 1993; 24 (4): 347–354. DOI: 10.1016/0046-8177(93)90080-Z.
204. Collins C.L., Ordonez N.G., Schaefer R. et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992; 141 (4): 827–833.
205. Dejmek A., Brockstedt U., Hjerpe A. Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma. APMIS. 1997; 105 (11): 889–894.
206. Dejmek A., Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn. Cytopathol. 2005; 32 (3): 160–166. DOI: 10.1002/dc.20202.
207. Fetsch P.A., Abati A., Hijazi Y.M. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998; 84 (2): 101–108.
208. Ordóñez N.G. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am. J. Surg. Pathol. 1997; 21 (12): 1399–1408.
209. Ordóñez N.G. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology. 1997; 31 (1): 25–30.
210. Kennedy A.D., King G., Kerr K.M. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J. Clin. Pathol. 1997; 50 (10): 859–862.
211. Clover J., Oates J., Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. 1997; 31 (2): 140–143.
212. González-Lois C., Ballestin C., Sotelo M.T. et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology. 2001; 38 (6): 528–534. DOI: 10.1046/j.1365-2559.2001.01157.x.
213. Delahaye M., van der Ham F., van der Kwast T.H. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn. Cytopathol. 1997; 17 (2): 115–120. DOI: 10.1002/(SICI)1097-0339(199708)17:2%3C115::AID-DC6%3E3.0.CO;2-F.
214. Garcia-Prats M.D., Ballestin C., Sotelo T. et al. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology. 1998; 32 (5): 462–472. DOI: 10.1046/j.1365-2559.1998.00405.x.
215. Dejmek A., Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology. 2000; 11 (1): 8–17. DOI: 10.1046/j.1365-2303.2000.00211.x.
216. Aerts J.G., Delahaye M., van der Kwast T.H. et al. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn. Cytopathol. 2006; 34 (8): 523–527. DOI: 10.1002/dc.20486.
217. al-Saffar N., Hasleton P.S. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. Eur. Respir. J. 1990; 3 (9): 997–1001.
218. Wick M.R., Loy T., Mills S.E. et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum. Pathol. 1990; 21 (7): 759–766. DOI: 10.1016/0046-8177(90)90036-5.
219. Bakir K., Koçer N.E., Deniz H., Güldür M.E. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma. Ann. Diagn. Pathol. 2004; 8 (6): 337–341. DOI: 10.1053/j.anndiagpath.2004.08.003.
220. Di Loreto C., Puglisi F., Di Lauro V. et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer. Lett. 1998; 124 (1): 73–78. DOI: 10.1016/S0304-3835(97)00466-7.
221. Attanoos R.L., Griffin A., Gibbs A.R. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factorreceptor, P-glycoprotein and Bcl-2. Histopathology. 2003; 43 (3): 231–238. DOI: 10.1046/j.1365-2559.2003.01686.x.
222. Bateman A.C., al-Talib R.K., Newman T. et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology. 1997; 30 (1): 49–56. DOI: 10.1046/j.1365-2559.1996.d01-562.x.
223. Ordóñez N.G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 2000; 24 (4): 598–606.
224. Cagle P.T., Brown R.W., Lebovitz R.M. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum. Pathol. 1994; 25 (5): 443–448. DOI: 10.1016/0046-8177(94)90115-5.
225. Husain A.N., Mirza M.K., Gibbs A. et al. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study. Lung Cancer. 2014; 83 (3): 324–328. DOI: 10.1016/j.lungcan.2013.12.009.
226. Kato Y., Tsuta K., Seki K. et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod. Pathol. 2007; 20 (2): 215–220. DOI: 10.1038/modpathol.3800732.
227. Kawamura K., Hiroshima K., Suzuki T. et al. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. Am. J. Clin. Pathol. 2013; 140 (4): 544–549. DOI: 10.1309/AJCPM2Z4NGIIPBGE.
228. Jo V.Y., Cibas E.S., Pinkus G.S. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014; 122 (4): 299–306. DOI: 10.1002/cncy.21392.
229. Ordóñez N.G. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005; 36 (4): 372–380. DOI: 10.1016/j.humpath.2005.01.019.
230. Pass H.I., Levin S.M., Harbut M.R. et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 2012; 367 (15): 1417–1427. DOI: 10.1056/NEJMoa1115050.
231. Agha M.A., El-Habashy M.M., El-Shazly R.A. Role of fibulin-3 in the diagnosis of malignant mesothelioma. Egypt. J. Chest. Dis. Tuberc. 2014; 63 (1): 99–105. DOI: 10.1016/j.ejcdt.2013.10.004.
232. Elgazzar M., Embarak S., Refat A.M. et al. Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions. Egypt. J. Chest Dis. Tuberc. 2014; 63 (4): 883–888. DOI: 10.1016/j.ejcdt.2014.08.001.
233. Creaney J., Dick I.M., Meniawy T.M. et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014; 69 (10): 895–902. DOI: 10.1136/thoraxjnl-2014-205205.
234. Jennings A.L., Davies A.N., Higgins J.P. et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57 (11): 939–944. DOI: 10.1136/thorax.57.11.939.
235. Abernethy A.P., Currow D.C., Frith P. et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. Br. Med. J. 2003; 327 (7414): 523–528. DOI: 10.1136/bmj.327.7414.523.
236. Bausewein C., Booth S., Gysels M., Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst. Rev. 2008; (2): CD005623. DOI: 10.1002/14651858.CD005623.
237. Galbraith S., Fagan P., Perkins P. et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J. Pain. Symptom Manage. 2010; 39 (5): 831–838. DOI: 10.1016/j.jpainsymman.2009.09.024.
238. Higginson I.J., Bausewein C., Reilly C.C. et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir. Med. 2014; 2 (12): 979–987. DOI: 10.1016/S2213-2600(14)70226-7.
239. Farquar M. Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? BMC Med. 2014; (12): 194. DOI: 10.1186/s12916-014-0194-2.
240. Caraceni A., Hanks G., Kaasa S. et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13 (2): e58–e68. DOI: 10.1016/S1470-2045(12)70040-2.
241. NICE. Opiods in palliative care: safe and effective prescribing of strong opiods in palliative care of adults, 2012. CG 140. Available at: https://www.nice.org.uk/guidance/cg140
242. NICE. Neuropathic pain – pharmacological management, 2013. CG 173. Available at: https://www.nice.org.uk/guidance/cg173/evidence
243. Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14 (2): 162–173. DOI: 10.1016/S1474-4422(14)70251-0.
244. Cramp F., Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst. Rev. 2012; (11): CD006145. DOI: 10.1002/14651858.CD006145.
245. Ruiz Garcia V., Lopez-Briz E., Carbonell Sanchis R. et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. 2013; (3): CD004310. DOI: 10.1002/14651858.CD004310.
Рецензия
Для цитирования:
Клинические рекомендации по диагностике и ведению больных со злокачественной мезотелиомой плевры (часть 2-я). Пульмонология. 2018;28(6):655-679. https://doi.org/10.18093/0869-0189-2018-28-6-655-679
For citation:
Clinical guidelines on diagnosis and management of patientsа with malignant pleural mesothelioma (рart 2). PULMONOLOGIYA. 2018;28(6):655-679. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-6-655-679
Просмотров: 2100
Послать статью по эл. почте 